Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding
Lihong Long, Chitoku Toda, Jing Kwon Jeong, Tamas L. Horvath, Sabrina Diano
Lihong Long, Chitoku Toda, Jing Kwon Jeong, Tamas L. Horvath, Sabrina Diano
View: Text | PDF
Research Article Metabolism

PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding

  • Text
  • PDF
Abstract

Activation of central PPARγ promotes food intake and body weight gain; however, the identity of the neurons that express PPARγ and mediate the effect of this nuclear receptor on energy homeostasis is unknown. Here, we determined that selective ablation of PPARγ in murine proopiomelanocortin (POMC) neurons decreases peroxisome density, elevates reactive oxygen species, and induces leptin sensitivity in these neurons. Furthermore, ablation of PPARγ in POMC neurons preserved the interaction between mitochondria and the endoplasmic reticulum, which is dysregulated by HFD. Compared with control animals, mice lacking PPARγ in POMC neurons had increased energy expenditure and locomotor activity; reduced body weight, fat mass, and food intake; and improved glucose metabolism when exposed to high-fat diet (HFD). Finally, peripheral administration of either a PPARγ activator or inhibitor failed to affect food intake of mice with POMC-specific PPARγ ablation. Taken together, our data indicate that PPARγ mediates cellular, biological, and functional adaptations of POMC neurons to HFD, thereby regulating whole-body energy balance.

Authors

Lihong Long, Chitoku Toda, Jing Kwon Jeong, Tamas L. Horvath, Sabrina Diano

×

Figure 8

Peripheral administration of either rosiglitazone or GW9662 fails to affect food intake in Pomc-Cre Ppargfl/fl mice.

Options: View larger image (or click on image) Download as PowerPoint
Peripheral administration of either rosiglitazone or GW9662 fails to aff...
(A) The effect of rosiglitazone administration on the food intake of lean control mice exposed to HFD (n = 5–6 per group). The percentage change in food intake before (vehicle treated) and after rosiglitazone treatment shows that rosiglitazone did not significantly alter food intake in Pomc-Cre Ppargfl/fl mice. (B) The effect of rosiglitazone administration on the body weight of lean control mice exposed to HFD. The percentage change in body weight before (vehicle treated) and after rosiglitazone treatment shows that rosiglitazone did not significantly alter body weight in Pomc-Cre Ppargfl/fl mice. (C) The effect of GW9662 administration on HFD-exposed mice for 16 weeks (n = 6 per group). The percentage change in food intake before (vehicle treated) and after GW9662 treatment shows that GW9662 failed to significantly decrease food intake in Pomc-Cre Ppargfl/fl mice. (D) The effect of GW9662 administration on the body weight of HFD-exposed mice for 16 weeks. The percentage change in body weight before (vehicle treated) and after GW9662 treatment shows that GW9662 failed to significantly decrease body weight in Pomc-Cre Ppargfl/fl mice. Data in the graphs are expressed as the mean ± SEM. *P < 0.05; **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts